The biosimilar opportunity

12 November 2018

Jean-Yves Brault, UK country manager for Mylan (Nasdaq: MYL), considers the much-needed copies of biologics that are now coming to the fore.

Healthcare systems around the world are facing unprecedented economic and social pressures. It is estimated that the UK’s National Health Service (NHS) is facing a funding gap of £30 billion (~$39 billion) by 2020.

Couple this with an aging population – recent Office of National Statistics figures show that the number of people living until 100 has increased by 85% in 15 years – a huge jump in the prevalence of chronic illness and the UK looks to be headed towards a very serious health crisis.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK